

SPARC/Sec/SE/2025-26/40

November 20, 2025

National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

BSE Limited,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Symbol: SPARC

Scrip Code: 532872

Dear Sir/Madam,

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Press Release about “Complete Response Letter Resubmission for PDP-716 NDA by Ocuvox”, which we shall be released after this intimation.

This is for your information and dissemination.

For **Sun Pharma Advanced Research Company Ltd.**

Kajal Damania
Company Secretary and Compliance Officer

Encl: As above



FOR IMMEDIATE RELEASE

SPARC announces Complete Response Letter Resubmission for PDP-716 NDA by Ocuvox

Mumbai, India, November 20, 2025 – Sun Pharma Advanced Research Company Ltd. (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872, "SPARC") today announced Complete Response Letter (CRL) resubmission to the US Food and Drug Administration (FDA) by Ocuvox Therapeutics Inc. (Ocuvox) for the PDP-716 New Drug Application (NDA).

The PDP-716 Complete Response resubmission addresses the FDA CRL issued in July 2023, stating unresolved facility inspection-related conditions at a third-party Active Pharmaceutical Ingredient (API) manufacturing facility. The FDA did not raise any concerns related to the efficacy or safety of PDP-716.

SPARC will provide an update after the FDA has determined that the response resubmission is complete.

About PDP-716:

PDP-716 is a novel, once daily, ophthalmic suspension of brimonidine tartrate 0.35%. PDP-716 was developed using SPARC's proprietary TearAct™ technology.

About Sun Pharma Advanced Research Company Ltd. (CIN - L73100GJ2006PLC047837):

Sun Pharma Advanced Research Company Ltd. (SPARC) is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery. SPARC aims to advance availability of treatment options for patients across the world. More information about the company can be found at www.sparc.life

Disclaimer:

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

Contact

Jaydeep Issrani
Tel +91 22 66455645, Ext: 5787
Tel Direct +91 22 6645 5787
Mobile +91-9820216916
E-mail jaydeep.issrani@sparcmail.com